Sermorelin + Ipamorelin Stack
A first-generation GHRH analog combined with a selective GHRP — often researched as a more conservative alternative to CJC-1295 + ipamorelin.
Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Why these two are stacked
Sermorelin is the first 29 amino acids of endogenous GHRH and has a short plasma half-life (~12 minutes). Ipamorelin is a selective GHRP. Combined, the pair produces a sharper, more naturalistic GH pulse than CJC-1295 + ipamorelin — preferred where preserving the natural diurnal GH pattern matters more than peak amplitude.
Same two-pathway logic as CJC-1295 + ipamorelin (GHRH + GHRP), but sermorelin's shorter action narrows the GH pulse and avoids prolonged elevation. This is the rationale for choosing this stack in older adults, in subjects with metabolic risk factors, or in long-term research where receptor sensitivity matters.
Researched together for
- •Synergistic GH pulse vs each peptide alone
- •Restoration of nocturnal GH amplitude in age-related decline
- •Sleep quality and recovery research
- •IGF-1 response with conservative dosing
- •Long-term receptor-sensitivity preservation
Sample weekly schedule
| When | Research protocol |
|---|---|
| Mon–Fri · evening | Single SC dose 60–90 minutes before bed, empty stomach. |
| Weekends off | Two off-days are common to limit pituitary desensitization. |
| Cycle length | Research cycles run 12–16 weeks; gentler than CJC-1295 + ipamorelin. |
Timing notes
- •Evening-only dosing aligns the induced GH pulse with the natural overnight pulse.
- •Some protocols add a second AM dose on training days, though most use PM only.
- •Sermorelin's short half-life makes timing more sensitive — late or post-meal dosing blunts the response.
Stack-specific considerations
- •Sermorelin is FDA-approved for pediatric GH deficiency but is researched off-label in adults.
- •Ipamorelin remains a research peptide; not FDA-approved.
- •Mild flushing, headache, or injection-site reactions are commonly noted.
- •Same general contraindications as CJC-1295 + ipamorelin: pregnancy, active malignancy, diabetic retinopathy.
Frequently asked
Q.How is sermorelin + ipamorelin different from CJC-1295 + ipamorelin?
Sermorelin has a much shorter half-life than CJC-1295, producing a sharper, more naturalistic GH pulse. Most research treats it as the conservative option for long-term use.
Q.Will IGF-1 rise as much as on CJC-1295 + ipamorelin?
Peak IGF-1 is typically lower. Whether that's a disadvantage or a feature depends on the research goal — gentler IGF-1 is preferred for long-term protocols.
Q.Is this stack better for older adults?
Research in adults over 50 often favors sermorelin-based stacks for that reason — gentler, more pulsatile, and easier to manage tolerance with.
Q.Can I combine sermorelin and ipamorelin in one syringe?
Yes, the two are chemically compatible and frequently co-administered in a single SC injection.
Q.How long should a cycle run?
Typical research cycles run 12–16 weeks. The gentler profile makes this stack a candidate for longer protocols.
Q.Is sermorelin FDA-approved?
Yes — for pediatric growth-hormone deficiency. Adult use for recovery / longevity goals is off-label and research-oriented.
Q.Does this stack help with sleep?
Endogenous GH pulses peak during slow-wave sleep, and research subjects consistently report improved sleep quality on GHRH + GHRP protocols. Sermorelin's natural pulse timing tends to suit sleep research particularly well.